Utrecht (The Nether­lands) — Gilde Health­care announ­ces the final closing of the new Venture&Growth Fund VI with a volume of EUR 740 million. Fund VI thus closes at the upper end of the target volume after announ­cing an initial closing of EUR 600 million in April of this year. The new fund focu­ses on fast-growing compa­nies that deve­lop solu­ti­ons for impro­ved health­care at lower costs.

Gilde Health­care invests in compa­nies in Europe and North America that are active in areas such as digi­tal health, medi­cal tech­no­logy and thera­peu­tics. Gilde Health­care Venture&Growth VI is an Article 9 fund in the context of the Sustainable Finance Disclo­sure Regu­la­tion (SFDR).

Inves­tors include compa­nies from the health­care sector, pension funds, banks, insu­rance compa­nies, funds of funds and sove­reign wealth funds, foun­da­ti­ons, family offices, entre­pre­neurs and the Gilde team.

Pieter van der Meer, Mana­ging Part­ner at Gilde Health­care: “The strong inte­rest from insti­tu­tio­nal inves­tors who want to make a sustainable impact with their invest­ments is a clear confir­ma­tion of our mission: inves­t­ing in solu­ti­ons that improve the quality of pati­ent care and are cost-effec­­tive at the same time. Our holi­stic and broad-based stra­tegy, which includes invest­ments in digi­tal health, medi­cal tech­no­logy and thera­peu­tics in parti­cu­lar, enables us to find the best and most cost-effec­­tive solu­tion for each indi­vi­dual pati­ent. With our team of expe­ri­en­ced indus­try experts, we help compa­nies to scale medi­cal inno­va­tions and make them acces­si­ble worldwide.”

Spen­ding on health­care in the western world is rising steadily and alre­ady exceeds 20% of GDP in the United States. Society as a whole needs cost-effec­­tive solu­ti­ons to coun­ter this growth in expen­dit­ure. Gilde Healthcare’s mission to invest in impro­ved health­care at lower cost is supported by the newly formed Impact Coun­cil, chai­red by the former Execu­tive Direc­tor of the Euro­pean Medi­ci­nes Agency (EMA).

The new fund will invest 10–70 million euros per port­fo­lio company. Toge­ther with the last Venture&Growth Fund V (2020) and Gilde Health­care Private Equity IV (2022), Gilde Health­care has raised EUR 1.7 billion in capi­tal in the last three years.

About Gilde Healthcare

Gilde Health­care is an inves­tor specia­li­zing in the health­care sector that mana­ges over 2.6 billion euros with two fund stra­te­gies: Venture&Growth and Private Equity. Gilde Healthcare’s Venture&Growth fund invests in fast-growing compa­nies in the fields of digi­tal health, medi­cal tech­no­logy and thera­peu­tics based in Europe and North America. Gilde Healthcare’s private equity fund invests in profi­ta­ble, medium-sized health­care compa­nies based in north-western Europe. Further infor­ma­tion can be found at: www.gildehealthcare.com